FDA advisers recommend making Narcan available over the counter


Independent advisers to the Food and Drug Administration on Wednesday unanimously recommended over-the-counter sales of Narcan, a nasal spray that can reverse opioid overdoses.
Narcan, known generically as naloxone, blocks the effects of opiates on the brain and is usually administered by first responders and outreach workers. Many public health experts have argued that it needs to be widely available without a prescription so people who use drugs, their friends, and relatives can have easy access to it. In 2021, there were 107,000 fatal drug overdoses in the United States, including several people who died after illegally buying pills like Xanax and Percocet that were laced with the synthetic opioid fentanyl.
The advisers determined that Narcan requires no training to administer and is "abundantly safe and effective even in infants, with almost no potential for misuse or abuse," The New York Times writes. Because of their unanimous vote, it's likely the FDA will approve an over-the-counter version of the medication in March, meaning it could hit store shelves and vending machines by summer.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The advisers all being in agreement "underscores the importance of moving this drug to greater access and also highlights the terrible risk of not acting in terms of making the drug more accessible," Maris C. Coyle, chairwoman of the advisory panel and an associate clinical professor at the Ohio State University College of Pharmacy, told the Times.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Can TrumpRx really lower drug prices?
Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
FDA OKs generic abortion pill, riling the right
Speed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shot
Speed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
The UK’s opioid crisis: why the stats don’t add up
The Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Why the FDA wants to restrict kratom-related products
In the Spotlight The compound is currently sold across the United States
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy